0001635088-26-000073.txt : 20260629 0001635088-26-000073.hdr.sgml : 20260629 20260629182306 ACCESSION NUMBER: 0001635088-26-000073 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260625 FILED AS OF DATE: 20260629 DATE AS OF CHANGE: 20260629 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sukhatme Mayukh CENTRAL INDEX KEY: 0001750050 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 261137325 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: C/O ROIVANT SCIENCES LTD. STREET 2: 7TH FLOOR, 50 BROADWAY CITY: LONDON PROVINCE COUNTRY: X0 ZIP: SW1H 0DB ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 7TH FLOOR, 50 BROADWAY CITY: LONDON NON US STATE TERRITORY: UNITED KINGDOM PROVINCE COUNTRY: X0 ZIP: SW1H 0DB BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 7TH FLOOR, 50 BROADWAY CITY: LONDON NON US STATE TERRITORY: UNITED KINGDOM PROVINCE COUNTRY: X0 ZIP: SW1H 0DB 4 1 wk-form4_1782771783.xml FORM 4 X0609 4 2026-06-25 0 0001635088 Roivant Sciences Ltd. ROIV 0001750050 Sukhatme Mayukh true C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM 1 1 0 0 President & CIO 0 Common Shares 2026-06-25 4 M 0 500000 3.85 A 19177617 D Common Shares 2026-06-25 4 S 0 500000 34.13 D 18677617 D Common Shares 2026-06-26 4 M 0 500000 3.85 A 19177617 D Common Shares 2026-06-26 4 S 0 500000 34.08 D 18677617 D Stock Option (Right to Buy) 3.85 2026-06-25 4 M 0 500000 0 D 2032-04-19 Common Stock 500000 14724363 D Stock Option (Right to Buy) 3.85 2026-06-26 4 M 0 500000 0 D 2032-04-19 Common Stock 500000 14224363 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Award of stock options to purchase Common Shares that is fully vested. By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme 2026-06-29